MarketLens
Sign Up

What Makes Elisrasib's ASCO 2026 Data So Significant

3 months ago
SHARE THIS ON:

What Makes Elisrasib's ASCO 2026 Data So Significant

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 week ago

NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger

NeOnc Technologies' Phase 2a readout for NEO100 in recurrent brain cancer showed a meaningful signal, shifting focus to whether results can support a registration path. The company's next milestone hi...
News1 months ago

Coherus Oncology: The Catalyst Rich Period Is Here

Coherus Oncology enters a catalyst-rich period with multiple clinical readouts for tagmokitug and casdozokitug in H2'26 and H1'27. Prior anti-CCR8 evidence supports potential efficacy in colorectal an...
Stock News1 months ago

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Erasca's ERAS-0015 showed 57% uORR in 2L KRAS G12X pancreatic cancer at 32 mg QD RDE, with 100% median relative dose intensity. Company plans registration-enabling lung cancer trial in H1 2027 and Pha...

Breaking News

View All →

Top Headlines

View More →
Stock News2 hours ago

Amazon Plane Crash Probe Examines Aircraft Speed, Runway Safeguards

Stock News2 hours ago

Crashed Amazon cargo jet struck two vehicles, ended up 1,300 feet past runway, NTSB says

Stock News2 hours ago

QQQ Charged 0.20% for Years. The Fee Only Fell After Shareholders Approved a Structural Change

Stock News4 hours ago

Nvidia Stock: Is It Still a Good Buy at $230?

Stock News5 hours ago

Nvidia CEO: Artificial General Intelligence Has ‘Arrived' With New OpenAI Model